Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DEPECA-1 - DEfeating PEnile Cancer 1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma

NCT07110038 is registered in ClinicalTrials.gov with Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest as lead sponsor.

NCT NCT07110038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07110038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DEPECA-1 - DEfeating PEnile Cancer 1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma
Lead sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase
Phase 2
Overall status
Recruiting
Start date
December 16, 2025
Completion date
November 30, 2030
Enrollment
25 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

penile squamous cell carcinoma (pscc)